Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution
October 31 2024 - 8:00AM
Business Wire
New offerings combine a variety of Medidata
technologies and learnings from thousands of previous trials to
streamline study management for Phase II and Phase III studies in
specified therapeutic areas, reinforcing FDA guidance for
patient-centered study design and execution
Medidata, a Dassault Systèmes brand and leading provider of
clinical trial solutions to the life sciences industry, has
introduced two new bundled offerings to meet the growing demands of
oncology and vaccine research. Medidata Oncology Solutions and
Medidata Vaccine Solutions reinforce the FDA guidance for
patient-centered endpoints, adaptive trial designs, and trial
diversity. By unifying key trial components such as real-time
patient-reported outcomes and imaging management, these bundled
solutions will aid sponsors by reducing trial complexity,
accelerating decision-making, and improving assessments of
treatment efficacy and safety.
"Oncology and vaccine trials face significant challenges in
recruiting diverse patients, ensuring rapid execution, and
maintaining and monitoring patient safety," said Joseph Schmidt,
chief operating officer, Medidata. "By making these new bundled
capabilities readily available to customers, we can deliver a
solution built on Medidata’s vast experience and expertise in these
two important therapeutic areas. These bundles are designed to help
customers navigate the complicated stages of these studies while
advancing life-saving treatments."
Medidata, with more than 25 years of oncology and vaccine
experience and the largest global trial datasets, has conducted
approximately 9,000 oncology studies and 750 trials in vaccines. In
2023, it was recorded that 93% of oncology drug approvals went
through Medidata. The company was also on the frontlines of
COVID-19, supporting hundreds of trials, including the development
of one of the most effective mRNA vaccines used to fight the
virus.
Both solutions deliver a unified data ecosystem by integrating
Medidata Rave EDC, Medidata eCOA, Medidata Rave Imaging, Medidata
Clinical Data Studio, and Health Record Connect. For more
information about Medidata’s new oncology and vaccine solution
bundles, visit our therapeutics landing page.
About Medidata
Medidata is powering smarter treatments and healthier people
through digital solutions to support clinical trials. Celebrating
25 years of ground-breaking technological innovation across more
than 34,000 trials and 10 million patients, Medidata offers
industry-leading expertise, analytics-powered insights, and the
largest patient-level historical clinical trial data set in the
world. More than 1 million registered users across approximately
2,200 customers trust Medidata’s seamless, end-to-end platform to
improve patient experiences, accelerate clinical breakthroughs, and
bring therapies to market faster. A Dassault Systèmes brand
(Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered
in New York City and has been recognized as a Leader by Everest
Group and IDC. Discover more at www.medidata.com and follow us
@Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide
business and people with collaborative virtual environments to
imagine sustainable innovations. By creating virtual twin
experiences of the real world with our 3DEXPERIENCE platform and
applications, our customers can redefine the creation, production
and life-cycle-management processes of their offer and thus have a
meaningful impact to make the world more sustainable. The beauty of
the Experience Economy is that it is a human-centered economy for
the benefit of all – consumers, patients and citizens. Dassault
Systèmes brings value to more than 350,000 customers of all sizes,
in all industries, in more than 150 countries. For more
information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS
logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA,
CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE,
SIMULIA and SOLIDWORKS are commercial trademarks or registered
trademarks of Dassault Systèmes, a European company (Societas
Europaea) incorporated under French law, and registered with the
Versailles trade and companies registry under number 322 306 440,
or its subsidiaries in the United States and/or other countries.
All other trademarks are owned by their respective owners. Use of
any Dassault Systèmes or its subsidiaries trademarks is subject to
their express written approval.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241031324962/en/
Medidata PR Medidata.PR@3ds.com
Analyst Relations medidata.AR@3ds.com
Big Tree Cloud (NASDAQ:DSY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Big Tree Cloud (NASDAQ:DSY)
Historical Stock Chart
From Nov 2023 to Nov 2024